This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

PDL BioPharma President Presents At Goldman Sachs Annual Global Healthcare Conference (Transcript)

PDL currently trades at around $6.20, $6.30, $6.50 a share and that's after we paid out just about $4 in dividends since 2009. So there has been a significant amount of shareholder value creation, considerably more than we anticipated.

Sapna Srivastava - Goldman Sachs

And can you help us describe the current status of the company and with the Queen's patent going off in 2014. And you've spoken a lot about trying to do smaller acquisitions. How should we think about PDLI ahead of 2014? Or will there be a PDLI ahead of 2014?

John McLaughlin

Sure. So our patents do expire towards the end of 2014, in December. We'll probably get paid for a while longer on our royalties because product that's made while the patents are still extant [ph]. Even if it's sold afterwards we still get paid and as you well know it takes seven, eight months to make an antibody. That's why they call it campaigns to make them.

So we'll probably get paid through 2015, maybe even into 2016 or thereabouts.

Sapna Srivastava - Goldman Sachs

At the same royalty rate.

John McLaughlin

Correct. But to the point of your question, at a certain point that inventory will expire. It will be used all up. And our shareholder base is about 80% dividend-sensitive. And so they've come to us and said, look, we like the fact that you are paying about a $0.60 dividend on a stock that trades for around $6. That's yield depending on the share price kind of bounces between 9% and 11%. In today's yield-hungry market is there any way to keep that going?

So what we have done is we've looked out to commercial stage companies as well as universities to see if there are royalties we can buy from them. In some cases we create synthetic royalties. So interestingly enough a group of companies that we've had some conversations with are commercial stage companies where you would say to yourself, a public commercial stage company, if they have to raise capital they should be able to do it. But some of those have seen their share prices be down. They're not necessarily happy where their share prices are and so we engage in conversations with them. Potentially with either debt structures, security against their commercial assets. Or synthetic royalties. If they don't have a real royalty we will simply say, pay us back based on a couple of percent off your sales.

2 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,031.14 +43.63 0.26%
S&P 500 1,984.13 -1.41 -0.07%
NASDAQ 4,518.9020 -48.6960 -1.07%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs